Glenmark Of India Seeks Government Probe Into Trial Manipulator
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals accused a government hospital participating in a trial of one of its drug trials of manipulating data and engaging in unfair practices, causing a halt of the trial. Glenmark filed a complaint with the Drug Controller General of India asking for an immediate audit of the hospital. At issue is Glenmark's Oglemilast asthma drug based on a PDE4 inhibitor molecule. The complaint also questioned whether the screening of volunteers was done properly. (Click here for more